Table 2.

Recommended Direct Acting Antiviral Regimens (in Ascending Order by Date of FDA Approval)

DAA (Commercial Name)	Dose/Duration	Recommended Use
Simeprevir (Olysio™) plus sofosbuvir (Sovaldi®)	150 mg + 400 mg PO daily with food 12 weeks	Alternative regimen only GT 1 No cirrhosis
Ledipasvir/sofosbuvir (Harvoni®)	90 mg/400 mg PO daily 12 to 24 weeks	GT 1, 4, 5, 6 No cirrhosis Compensated cirrhosis (GT 1, 4) Decompensated cirrhosis (+RBV or 24 weeks; GT 1, 4, 5, 6)
Paritaprevir/ritonavir/ombitasvir and dasabuvir (Viekira Pak®) plus Ribavirin	150 mg/100 mg/25 mg and 600 mg dasabuvir PO daily or 250 mg dasabuvir twice daily + weight-based RBV 12 weeks	Alternative regimen only GT 1, 4 No cirrhosis Compensated cirrhosis (GT 1b, 4)
Daclatasvir (Daklinza™) plus sofosbuvir (Sovaldi®)	60 mg + 400 mg PO daily 12 to 24 weeks	Alternative regimen only GT 1, 2, 3 No cirrhosis Compensated cirrhosis (GT 2, 3) Decompensated cirrhosis (+RBV or 24 weeks; GT 1, 2, 3, 4)
Elbasvir/grazoprevir (Zepatier®)	50 mg/100 mg PO daily 12 to 16 weeks	GT 1, 4 No cirrhosis Compensated cirrhosis ESRD (GT 1, 4)
Sofosbuvir/velpatasvir (Epclusa®)	400 mg/100 mg PO daily 12 to 24 weeks	GT 1, 2, 3, 4, 5, 6 No cirrhosis Compensated cirrhosis Decompensated cirrhosis (+RBV or 24 weeks; GT 1, 2, 3, 4, 5, 6)
glecaprevir/pibrentasvir (Mavyret™)	300 mg/120 mg PO daily 8 to 16 weeks	GT 1, 2, 3, 4, 5, 6 No cirrhosis Compensated cirrhosis ESRD
Sofosbuvir/velpatasvir/voxilaprevir (Vosevi®)	400 mg/100 mg/100 mg daily 12 weeks	Alternative regimen only GT 3 Compensated cirrhosis

Note: GT = Genotype; PO = by mouth; ESRD = end stage renal disease; PI = protease inhibitor; +RBV = add ribavirin; P/R = peginterferon/ribavirin

Source: American Association for the Study of Liver Diseases & Infectious Diseases Society of America, 2019